Michael A Proschan (M Proschan, Michael Proschan)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Monoclonal Antibody

Hiv Infected Patients

Top Venues

Statistics in medicine

Science translational medicine

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

This page only lists publications with an associated author ORCID identifier.

Publications

Michael A Proschan, Martha Nason, Ana M Ortega-Villa, Jing Wang
Changing interim monitoring in response to internal clinical trial data. Biometrics 80 (1) (2024)
Michael A Proschan, Dean A Follmann
A note on familywise error rate for a primary and secondary endpoint. Biometrics (2022)
Shannon K Gallagher, Jing Wang, Keith Lumbard, Lori E Dodd, Michael A Proschan
Noninferiority testing with censoring when the event rate is low. Statistics in medicine 41 (25) (2022)
Michael A Proschan, Scott Evans
Reply to Villar et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 73 (3) (2021)
Michael A Proschan, Scott Evans
Reply to Chandereng and Chappell. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 73 (3) (2021)
Michael A Proschan
Discussion on "Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment for binary, ordinal, and time-to-event outcomes". Biometrics (2021)
Michael A Proschan, Erica H Brittain
A primer on strong vs weak control of familywise error rate. Statistics in medicine 39 (9) (2020)
Michael A Proschan, Pamela A Shaw
Diagnosing fraudulent baseline data in clinical trials. PloS one 15 (9) (2020)
Lori E Dodd, Dean A Follmann, Michael A Proschan, Jing Wang, Denis Malvy, Johan van Griensven, Iza Ciglenecki, Peter W Horby, Rashid Ansumana, Jia-Fu Jiang, Richard T Davey, Henry Clifford Lane, Aurelie Gouel-Cheron
A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Science translational medicine 11 (520) (2020)
Michael A Proschan, Lori E Dodd
Re-randomization tests in clinical trials. Statistics in medicine 38 (12) (2019)
Michael C Sneller, Katherine E Clarridge, Catherine Seamon, Victoria Shi, Marek D Zorawski, Jesse Shawn Justement, Jana Blazkova, Erin D Huiting, Michael A Proschan, Jorge Rodrigo Mora, Michael Shetzline, Susan L Moir, Henry Clifford Lane, Tae-Wook Chun, Anthony S Fauci
An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals. Science translational medicine 11 (509) (2019)
Michele Di Mascio, Jeffrey D Lifson, Sharat Srinivasula, I Kim, P DeGrange, Brandon F Keele, Aaron J Belli, Keith A Reimann, Y Wang, Michael A Proschan, Henry Clifford Lane, Anthony S Fauci
Evaluation of an antibody to α4β7 in the control of SIVmac239-nef-stop infection. Science (New York, N.Y.) 365 (6457) (2019)
Michael C Sneller, J Shawn Justement, Kathleen R Gittens, Mary E Petrone, Katherine E Clarridge, Michael A Proschan, Richard Kwan, Victoria Shi, Jana Blazkova, Eric W Refsland, Daryl E Morris, Kristen W Cohen, M Juliana McElrath, Rong Xu, Michael A Egan, John H Eldridge, Erika Benko, Colin Kovacs, Susan Moir, Tae-Wook Chun, Anthony S Fauci
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Science translational medicine 9 (419) (2018)